EP300 and leukemia: In line with our ex vivo observations, EP300-ZNF384-expressing NALM-6 cells responded remarkably to doxorubicin treatment in vivo, resulting in a significantly decreased percentage of hCD19+ cells in mouse BM and a reduced leukemia burden in the liver (Fig. 6E, F, and S5).